Analysis of generic and branded drugs

Johns Hopkins study suggests medical errors are third-leading cause of death in US Abraham Flexner on staff at the Carnegie Foundationand funded by the Rockefeller Foundation'sourced' the American 'medical' reformation following US Congressional acceptance of the " Flexner Report. Kay, whom a MIT News Office obituary referred to as "one of the outstanding historians of biology of her generation," argued that the "new biology" was largely forged by the Rockefeller Foundation and its subsidiary program at the California Institute of Technology Caltech through a consensus between a scientific elite and a business elite whose broader aims centered on eugenics and the need to create a mechanism of social control and human engineering: Rather, the rise of the new biology was an expression of the systematic cooperative efforts of America's scientific establishment - scientists and their patrons - to direct the study of animate phenomena along selected paths toward a shared vision of science and society. Kay American Medical Association urges ban on TV drug ads Practioners of alternative healing methods consider the application of chemical toxins and surgeries to be 'allopathic medicine'.

Analysis of generic and branded drugs

Key drivers of the market include an increase in patient awareness and education levels and growing base of geriatric population.

Rising adoption of a sedentary lifestyle and increasing incidence of lifestyle diseases are further anticipated to fuel growth. However, the industry is estimated to witness a decline in revenue over the forecast period owing to the patent expiration of key drugs in Moreover, reported side effects from the existing drugs are negatively affecting the industry growth.

Availability of cost-effective counterfeit drugs is further expected to decrease the valuation of the branded erectile dysfunction drugs. North America erectile dysfunction drugs market, by product, -USD Million Government reforms and public awareness initiatives in developing regions of Asia Pacific and Latin America are expected to drive market growth during the forecast period.

Economic development, healthcare infrastructure establishment, and increasing target population are estimated to provide potential growth platforms for this industry in these regions.

Novel molecule combinations and drug delivery techniques such as the use of creams and pellets that show better efficacy and performance are expected to become an opportunity for the erectile dysfunction drugs industry.

Product Insights The industry is likely to experience a decline in revenue mainly due to the expiration of patents of key drug molecules around The main line of drugs for erectile dysfunction treatment includes Vitaros, Zydena, Stendra, Levitra, Cialis, and Viagra. Viagra sildenafil citrate is one of the most widely distributed products worldwide.

It is distinguished from other PDE 5 inhibitors for its longer duration of action and lesser incidences of side effects such as vision disturbances and muscle pain. Viagra dominated the overall industry in terms of revenue and was valued at over USD 2, million in Despite its patent expiration by in the U.

Analysis of generic and branded drugs

However, the drug demand is expected to witness a decline by owing to the emergence of numerous cheap and similar acting generic versions of blockbuster drugs after their patent expirations. Rising prevalence of erectile dysfunction causing infections, growing base of geriatric population, flourishing generic drugs industry, and social stigma are the main factors accounting for the fastest growth of this region.

The industry for branded erectile dysfunction drugs is consolidated with key players involved in intense competition and rivalry. However, the company's market share is likely to decline over the forecast period owing to the patent expiry of Viagra in Generics are expected to boost industrial growth.

In addition, post-patent expiration, mergers, acquisitions and collaborations activities, and geographic expansion are expected to keep industry rivalry at higher levels over the forecast period.Figure 4: Analysis of cost of single dose of Inj ceftriaxone 1gm Branded (Brand A-E) vs Generic (Brand G).

Bhosle et al; Comparison of Generic and Branded Drugs Annals of International Medical and Dental Research, Vol (3), Issue (1) Page 4. A programme to encourage clinicians to switch people to generic antiretroviral drugs saved the NHS almost £10 million in the financial year , Dr Laura Waters of NHS England’s Clinical Reference Group for HIV services told the recent joint British HIV Association (BHIVA) and British Association for Sexual Health and HIV (BASHH) conference in Edinburgh.

Target Branded Drugs as a Percentage of All Filled Prescriptions in the Class in , Across Days Receiving Target Drug–Sponsored Meals.

Analysis of generic and branded drugs

The U.S. Food and Drug Administration today announced a new comprehensive plan for tobacco and nicotine regulation that will serve as a multi-year roadmap to better protect kids and significantly reduce tobacco-related disease and death.

Higher prices, and greater use of higher-priced drugs, make the U.S. an outlier on prescription drug spending Prescription drug spending in the U.S. far exceeds that in other high-income countries U.S. health care spending, per capita and as a percent of GDP, dwarfs that of any other high-income.

Brief report Recent trends in brand-name and generic drug competition Henry Grabowski Duke University, Durham, NC, USA encouraging more generic competition for brand-name drugs, the Hatch-Waxman Act also established new analysis contained information about all drugs experi-.

Intellectual Property : Law : Legal News & Analysis